Results 251 to 260 of about 15,628 (311)
Some of the next articles are maybe not open access.

A real-world disproportionality analysis of cidofovir from the FDA adverse event reporting system (FAERS) database.

Expert Opinion on Drug Safety
BACKGROUND Cidofovir, an antiviral drug used to treat cytomegalovirus retinitis in AIDS patients. While effective against several viruses, cidofovir's nephrotoxicity and other adverse events (AEs) limit its broader use. This study aims to evaluate the AE
Chengzhi Liu   +3 more
semanticscholar   +1 more source

Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports.

Expert Opinion on Drug Safety
BACKGROUND Topical minoxidil, approved by the FDA in the 1980s, has been widely used to manage androgenetic alopecia. While effective, several adverse events (AEs) related to its use, especially those not well-documented on product labels, remain a ...
Yanbo Li, Bo Liu, Wei Wu, Jian Li
semanticscholar   +1 more source

Adverse events reporting of edaravone: a real-world analysis from FAERS database

Scientific Reports
For individuals with amyotrophic lateral sclerosis (ALS), intravenous edaravone is approved as a disease-modifying medication; yet, there have been many reports of adverse events (AEs).
Qi Shang   +3 more
semanticscholar   +1 more source

Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022

Expert Review of Clinical Pharmacology
Background Metformin has the potential for treating numerous diseases, but there are still many unrecognized and unreported adverse events (AEs). Methods We selected data from the United States FDA Adverse Event Reporting System (FAERS) database from the
Yikuan Du   +13 more
semanticscholar   +1 more source

Drug-induced autoimmune-like hepatitis: A disproportionality analysis based on the FAERS database

PLoS ONE
Background Drug-induced autoimmune-like hepatitis (DI-ALH) is a potentially life-threatening condition that can lead to acute liver failure and necessitate liver transplantation. While the association between certain drugs and DI-ALH has been documented,
Wangyu Ye   +5 more
semanticscholar   +1 more source

Haemorrhage-related adverse events profles of lenvatinib and pembrolizumab alone or in combination: a real-world pharmacovigilance study based on FAERS database

BMC Pharmacology and Toxicology
Limited understanding exists regarding the haemorrhagic risk resulting from potential interactions between lenvatinib and pembrolizumab. We investigated haemorrhagic adverse events (ADEs) associated with co-administration of lenvatinib and pembrolizumab ...
Shiqiao Wang   +7 more
semanticscholar   +1 more source

Real-World Safety of Vedolizumab in Inflammatory Bowel Disease: A Retrospective Cohort Study Supported by FAERS Signal Analysis

Pharmaceuticals
Background/Objectives: Vedolizumab is a gut-selective anti-integrin monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD). While clinical trials have demonstrated a favorable safety profile, real-world studies are essential ...
Bojana Milašinović   +8 more
semanticscholar   +1 more source

Neratinib safety evaluation: real-world adverse event analysis from the FAERS database

Frontiers in Pharmacology
Aims Neratinib has emerged as significant theraputic option for breast cancer treatment. However, despite its approval, numerous adverse drug events (ADEs) associated to it remain unrecognized and unreported.
Yunhe Fan   +7 more
semanticscholar   +1 more source

Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database

Scientific Reports
Lacosamide was the first approved third-generation antiepileptic drug. However, real-world data regarding its adverse cardiac reactions in large samples still need to be completed.
Chengcheng Yang   +4 more
semanticscholar   +1 more source

Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database.

International Journal of Surgery
BACKGROUND With the clinical integration of sugammadex, a selective relaxant-binding agent, the approach to reversing neuromuscular blockade is revolutionized. Despite its efficacy, sugammadex's adverse reactions range from mild symptoms to severe cases,
Hongtao Liu   +4 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy